News

Low-intensity ultrasound boosts therapeutic delivery to the brain

Noninvasive low-intensity focused ultrasound (LIFU) temporarily opened the blood-brain barrier to allow molecules to enter the brains of Parkinson’s disease patients, a study reports. In nonhuman primates, LIFU safely enhanced the delivery of a gene therapy model using a harmless, modified virus directly to the striatum, a region affected…

AAN 2023: P2B001 controls symptoms with less sleepiness

The investigational combination therapy P2B001 was similar to Mirapex (pramipexole) at controlling symptoms of Parkinson’s disease in a clinical trial. But patients treated with P2B001 were less likely to experience sleepiness and fewer had orthostatic hypotension (a sudden drop in blood pressure on standing) as side effects. Lawrence Elmer,…

AAN 2023: IPX203 still safe, effective in extension study

IPX203, Amneal Pharmaceuticals‘ investigational extended-release carbidopa/levodopa (CD/LD) treatment for Parkinson’s disease, continued to exhibit a favorable safety and efficacy profile during the open-label extension part of the Phase 3 RISE-PD trial. “IPX203 remained as efficacious and safe as it was shown during the RISE-PD study, and the vast…

Exercise, especially mind-body, eases motor symptoms

Physiotherapy, and mind-body exercise particularly, can meaningfully ease motor symptoms of Parkinson’s disease, a recent meta-analysis of clinical trial data involving more than 2,500 people reported. Mind-body exercise refers to practices that focus on the connection between the body, breath, and the mind, such as yoga, tai chi, or…